Daewoong Pharmaceutical Launches Three Types of EGFx Downtime Ampoule at Pharmacies

On May 19, Daewoong Pharmaceutical announced the launch of three types of ‘EGFx Downtime Ampoule’, a cosmetic product designed to systematically manage the condition of skin that has been stimulated after professional skincare procedures.

Product images of Daewoong Pharmaceutical’s three types of ‘EGFx Downtime Ampoule’. Daewoong Pharmaceutical

View original image

After professional skin treatments, a temporary decline in skin condition, known as ‘downtime’, occurs due to damage to the skin barrier. Since this period is the initial stage of recovery for sensitive skin, appropriate management is crucial until the skin barrier returns to a healthy state.

The new products are EGF-based repair solutions specifically formulated to intensively care for the skin during the downtime phase. EGF (epidermal growth factor), which is increasingly used in a variety of fields from pharmaceuticals to cosmetics, is a naturally occurring protein that induces proliferation and growth of skin cells and is known as a key ingredient involved in the skin’s recovery process.

EGFx Downtime Ampoule is formulated with a high concentration of EGF at the maximum level permitted under cosmetic regulations, 10 ppm. The product leverages Daewoong Pharmaceutical’s proprietary EGF manufacturing technology and patented nanoliposome technology to further enhance EGF absorption into the skin. By nano-sizing the large EGF molecules to about 1/100 the thickness of a human hair (diameter 100–200nm), absorption is increased. The product also uses Daewoong Pharmaceutical’s rigorously purified high-purity raw material, ‘DW-EGF’, ensuring the reliability of ingredient quality.

DW-EGF is an original EGF raw material developed by Daewoong Pharmaceutical based on research dating back to 1992. In 1995, the company succeeded in developing technology for the mass production of proteins with the same structure and activity as human EGF. After further clinical studies, in 2001, the company obtained approval from the Ministry of Food and Drug Safety for the world’s first genetically engineered EGF drug. It has since been used in various wound care fields, including the diabetic foot ulcer treatment ‘EGF Solution’ and the wound and skin ulcer care ointment ‘EGF Ointment’. In 2008, Daewoong Pharmaceutical was awarded the International Nonproprietary Name (INN) ‘Nepidermin’ by the World Health Organization (WHO).

The new product line-up is based on DW-EGF and allows for more precise care tailored to the skin condition following different procedures: Post-Laser, Post-Skinbooster, and Post-Eltherma. Each product features the key ingredient EGF, combined with a unique formula addressing specific downtime skin concerns, enabling customized care for various skin conditions.

‘Post-Laser’ contains niacinamide and ceramide to help reduce temporary redness and provide brightening care, while ‘Post-Skinbooster’ focuses on skin barrier care with panthenol, cica, and vitamin K. ‘Post-Eltherma’ is formulated with PDRN and collagen, targeting skin elasticity improvement.

The three types of EGFx Downtime Ampoule are available at pharmacy cosmetics counters. While the primary target consumer group is women in their 20s and 30s, the products were developed to reflect the needs of all consumers who prioritize post-procedure downtime care.

Eunkyung Park, Chief of CH Marketing Division at Daewoong Pharmaceutical, said, “EGFx is a line designed for customized care according to the skin condition after professional treatments. As the Downtime Ampoule is planned specifically for the crucial initial seven days after skincare procedures, we expect it will help consumers achieve systematic skin management.” She added, “With the launch of the EGFx line, we aim to provide consumers with a more professional derma-cosmetic experience and to strengthen our competitiveness in the global market going forward.”

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.